Literature DB >> 18984462

Preface. Hepatic fibrosis: pathogenesis, diagnosis, and emerging therapies.

Scott L Friedman1.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18984462     DOI： 10.1016/j.cld.2008.07.009

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN： 1089-3261            Impact factor:   6.126


× No keyword cloud information.
  10 in total

1.  Versican: a novel modulator of hepatic fibrosis.

Authors:  Terence N Bukong; Sean B Maurice; Barinder Chahal; David F Schaeffer; Paul J Winwood
Journal:  Lab Invest       Date:  2016-01-11       Impact factor: 5.662

Review 2.  Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies?

Authors:  Alex Boye; Yu-Hong Zou; Yan Yang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients.

Authors:  Xu-Dong Liu; Jian-Lin Wu; Jian Liang; Tao Zhang; Qing-Shou Sheng
Journal:  World J Gastroenterol       Date:  2012-06-14       Impact factor: 5.742

Review 4.  Promising therapies for treatment of nonalcoholic steatohepatitis.

Authors:  Mazen Noureddin; Alice Zhang; Rohit Loomba
Journal:  Expert Opin Emerg Drugs       Date:  2016-08-28       Impact factor: 4.191

5.  Inflammation rapidly modulates the expression of ALDH1A1 (RALDH1) and vimentin in the liver and hepatic macrophages of rats in vivo.

Authors:  Kyoko Ito; Reza Zolfaghari; Lei Hao; A Catharine Ross
Journal:  Nutr Metab (Lond)       Date:  2014-11-25       Impact factor: 4.169

6.  Parameters associated with significant liver histological changes in patients with chronic hepatitis B.

Authors:  Li Xiao; Jianchun Xian; Yang Li; Aiwen Geng; Xiuzhen Yang; Libin Han; Hongtao Xu
Journal:  ISRN Gastroenterol       Date:  2014-01-28

Review 7.  Clinical Advancements in the Targeted Therapies against Liver Fibrosis.

Authors:  Ruchi Bansal; Beata Nagórniewicz; Jai Prakash
Journal:  Mediators Inflamm       Date:  2016-11-24       Impact factor: 4.711

8.  Vatalanib, a tyrosine kinase inhibitor, decreases hepatic fibrosis and sinusoidal capillarization in CCl4-induced fibrotic mice.

Authors:  Ling-Jian Kong; Hao Li; Ya-Ju Du; Feng-Hua Pei; Ying Hu; Liao-Liao Zhao; Jing Chen
Journal:  Mol Med Rep       Date:  2017-03-15       Impact factor: 2.952

9.  The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study.

Authors:  Barbara Rossetti; Roberta Gagliardini; Gaetana Sterrantino; Vincenzo Colangeli; Alessandra Latini; Manuela Colafigli; Francesca Vignale; Stefano Rusconi; Antonio Di Biagio; Giancarlo Orofino; Ivano Mezzaroma; Vincenzo Vullo; Daniela Francisci; Claudio Mastroianni; Michele Trezzi; Benedetta Canovari; Silvia Lamonica; Arturo Ciccullo; Alberto Borghetti; Antonella DʼArminio Monforte; Simona Di Giambenedetto; Andrea De Luca
Journal:  J Acquir Immune Defic Syndr       Date:  2019-05-01       Impact factor: 3.731

10.  Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats.

Authors:  Cheng Liu; Zongguo Yang; Lei Wang; Yunfei Lu; Bozong Tang; Hui Miao; Qingnian Xu; Xiaorong Chen
Journal:  BMC Gastroenterol       Date:  2015-11-16       Impact factor: 2.847
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.